During the quarters ended March 31, 2025 and March 31, 2024, the Company recognized restructuring costs related to certain departmental reorganizations totaling $1.5 million, and a reduction-in-force totaling $2.2 million, respectively. One-time termination benefits provided in either case included severance, continuation of health insurance coverage and other benefits for a specified period of time.

Restructuring costs have been recognized in the accompanying consolidated statement of operations as follows:


	Three Months Ended March 31,
		2025		2024
		(In thousands)
Restructuring costs:
Cost of revenue		$	44	$	88
Research and development expense		229		116
Sales and marketing expense		748		1,104
General and administrative expense		495		897
Total		$	1,516	$	2,205

At March 31, 2025, a payable of $0.7 million related to reorganization activities in the first quarter of 2025 was included in "Accrued expenses and other current liabilities" in the accompanying consolidated balance sheet.